GI antibiotics: Difference between revisions

No edit summary
No edit summary
 
Line 62: Line 62:
{{Antibiotics by diagnosis navigation}}
{{Antibiotics by diagnosis navigation}}


=References=
==References==
<references/>
<references/>
[[Category:ID]] [[Category:Pharmacology]]
[[Category:ID]] [[Category:Pharmacology]]

Latest revision as of 20:20, 15 April 2019

Appendicitis

Coverage should extend to E. coli, Klebsiella, Proteus, and Bacteroides (an anaerobe)

Adult Simple Appendicitis

Antibiotic prophylaxis should be coordinated with surgical consult

Options:

Pediatric Simple Appendicitis

Options:

Adult Complicated Appendicitis

Defined as perforation, abscess, or phlegmon

Options:

Pediatric Complicated Appendicitis

Options:

Cautious use should be applied to use of fluoroquinolones in complicated pediatric appendicitis due to the risk of tendon injury

Cholecystitis

Most often isolated organisms are Escherichia coli, Klebsiella pneumonia, and anaerobes, especially Bacteroides fragilis

Uncomplicated

Pathogenicity of Enterococci remains unclear and specific coverage is not routinely suggested for community-acquired infections[1]

Complicated or Healthcare Associated

Examples of complication include severe sepsis or hemodynamic instability

  • Vancomycin 15-20mg/kg PLUS any of the following options

Options:

Pediatric

Clostridium Difficile

Mild/Moderate Infection

  • Vancomycin 125 mg PO four times daily for 10 days
  • Fidaxomicin 200 mg PO two times daily for 10 days
  • Metronidazole 500mg PO or IV three times daily for 10 days (third line therapy)

Pediatric:

  • Vancomycin 10mg/kg PO QID x 10 days (max 125mg/dose)
  • Fidaxomicin 200mg PO BID x 10 days (>12yr and >40kg); weight-based for younger
  • Metronidazole 7.5mg/kg PO/IV TID x 10 days (max 500mg/dose) (third line)

Serious Infection

Diverticulitis

Uncomplicated

First, consider whether antibiotics are needed:

  • In immunocompetent patients with mild uncomplicated diverticulitis (no systemic signs, able to tolerate PO, reliable follow-up), a trial of supportive care alone (bowel rest, hydration, pain control) without antibiotics is reasonable[2][3]
  • Antibiotics ARE indicated if: immunocompromised, significant comorbidities/frailty, CRP >140 mg/L, WBC >15 × 10⁹/L, refractory symptoms, vomiting, or CT showing fluid collection or longer segment of inflammation[2]

If antibiotics are prescribed (4-7 day course preferred):[2]

Preferred:

  • Amoxicillin/Clavulanate 875/125mg PO Q8hrs x 5 days (or Augmentin XR 2 tablets BID [each tablet 1gm amoxicillin 62.5mg clavulanate])[4][5]
    • Equally effective as fluoroquinolone + metronidazole with lower C. difficile risk (especially in patients ≥65 years)[5]
    • Avoids FDA black box fluoroquinolone risks (tendinopathy, neuropathy, aortic dissection, CNS effects)[6]

Alternatives (penicillin allergy or intolerance):

Complicated

Options:

General Sick

Intra-Abdominal Sepsis/Peritonitis

Harbor-UCLA Santa Monica-UCLA Other
Primary
Allergy or prior exposure

Pediatric

Infectious Diarrhea

Campylobacter jejuni

Pediatric:

Entamoeba Histolytica

Giardia lamblia

Microsporidium

Cryptosporidium

Salmonella (non typhoid)

  • Treatment is not recommended routinely but should be considered if:
  • Immunocompromised
  • Age<6 mo or >50yo
  • Has any prostheses
  • Valvular heart disease
  • Severe Atherosclerosis
  • Active Malignancy
  • Uremic

Options: Immunocompromised patients should have 14 days of therapy

Pediatric:

  • Treatment recommended if age <6 months, immunocompromised, or bacteremia
  • Ceftriaxone 50-75mg/kg IV daily x 5 days (max 2g)
  • TMP/SMX 8mg/kg/day (TMP) PO divided BID x 5 days
  • Azithromycin 10mg/kg PO day 1, then 5mg/kg/day x 4 days

Shigella

Treatment extended for 10 days if immunocompromised'

Pediatric:

  • Azithromycin 10mg/kg PO day 1 (max 500mg), then 5mg/kg/day x 4 days
  • Ceftriaxone 50mg/kg IM/IV daily x 5 days (max 2g)
  • TMP/SMX 8mg/kg/day (TMP) PO divided BID x 5 days (if susceptible)

Vibrio Cholerae

Yersinia enterocolitica

Antibiotics are not required unless patient is immunocompromised or systemically ill

Peritoneal Dialysis Associated Peritonitis

Empiric Therapy (IP)

10- to 14-day course of intraperitoneal (IP) antibiotics that are administered by the patient on an outpatient basis or IV antibiotics and intraperitoneal for admitted patients
  • Vancomycin 30mg/kg loading followed by 0.6 mg/kg IP daily PLUS[8]
  • Ceftazidime 1g IP daily OR
  • Gentamicin 0.6mg/kg daily
  • Catheter removal/exchange is usually only done if IP antibiotics fail (fungal, pseudomonal), and should be done in consultation with a nephrologist[9]

Empiric Tharapy (IV)

Although IP antibiotics are preferred IV antibiotics can be considered with coordination with nephrology for dosing. Coverage should be the same as IP antibiotics [10][11]

Traveler's Diarrhea

Options for Adults:

Typhoid Fever

Oral therapy with Quinolone Susceptibility

Parenteral Therapy with Quinolone Susceptibility

Parenteral Therapy with Quinolone Resistance

if nalidixic acid resistant, assume fluoroquinolone resistant
OR
  • Cefixime 10-15 mg/kg IV q 12 hrs x 8 days

Oral Therapy with Quinolone Resistance

  • Azithromycin 1 g PO daily x 5 days
  • Amoxicillin Not 1st line treatment; 50-100mg/kg/day PO divided q6-8h x 14 days; First Dose: 12.5mg-33.3mg/kg PO x 1
  • Amoxicillin Not 1st line treatment; 50-100mg/kg/day PO divided q6-8h x 14 days

Pediatric

  • Ceftriaxone 50-80mg/kg IV daily x 10-14 days (max 2g)
  • Azithromycin 10-20mg/kg PO daily x 5-7 days (max 1g)
  • Cefixime 15-20mg/kg/day PO divided BID x 7-14 days (max 400mg/dose)

See Also

Antibiotics by diagnosis

For antibiotics by organism see Microbiology (Main)

References

  1. Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5
  2. 2.0 2.1 2.2 Peery AF, Shaukat A, Strate LL. AGA Clinical Practice Update on Medical Management of Colonic Diverticulitis: Expert Review. Gastroenterology. 2021;160(3):906-911.e1. doi:10.1053/j.gastro.2020.09.059
  3. Qaseem A, et al. Diagnosis and Management of Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2022;175(3):399-415.
  4. Balasubramanian I et al. Out-Patient Management of Mild or Uncomplicated Diverticulitis: A Systematic Review. Dig Surg. 2017;34(2):151-160.
  5. 5.0 5.1 Gaber CE, Kinlaw AC, Edwards JK, et al. Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis: Two Nationwide Cohort Studies. Ann Intern Med. 2021;174(6):737-746. doi:10.7326/M20-6315
  6. 6.0 6.1 FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. July 26, 2016.
  7. Wilkins T et al. Diagnosis and Management of Acute Diverticulitis. Am Fam Physician. 2013 May 1;87(9):612-620.
  8. Li PK, et al: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393 Fulltext
  9. Akoh JA. Peritoneal dialysis associated infections: An update on diagnosis and management. World J Nephrol. 2012 Aug 6; 1(4): 106–122.
  10. Manley HJ, Bailie GR, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2001;21 :378-85
  11. Wong et al. Intravenous Antibiotics with Adjunctive Lavage in Refractory Peritonitis. Intravenous Antibiotics with Adjunctive Lavage in Refractory Peritonitis
  12. Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5
  13. Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
  14. Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8
  15. Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
  16. Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
  17. DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15